Short Communication - Asian Journal of Biomedical and Pharmaceutical Sciences (2023) Volume 13, Issue 101
Pharmacokinetics in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Implications for Treatment
p> Hanna J. Lee *
Department of Pharmaceutics and Pharmaceutical Technology, University of Uyo, Uyo, Nigeria
- *Corresponding Author:
- Hanna J. Lee
Department of Pharmaceutics and Pharmaceutical Technology
University of Uyo
E-mail: Danial Esmaelnezhad@u.edu.ng
Received:31-Aug -2023, Manuscript No. AABPS-23-114200; Editor assigned: 05-Sep-2023, PreQC No. AABPS-23-114200 (PQ); Reviewed:19-Sep-2023, QC No. AABPS-23-114200; Revised:25-Sep-2023, Manuscript No. AABPS-23-114193 (R); Published: 30-Sep-2023, DOI:10.35841/ aabps-13.101.200
Citation: J. Lee H. Pharmacokinetics in pediatric patients with moderate to severe plaque psoriasis: Implications for treatment. Asian J Biomed Pharmaceut Sci. 2023;13(101):200
Pediatric obesity is a significant public health concern, with far-reaching consequences for the health and well-being of children and adolescents. While lifestyle modifications, including dietary changes and increased physical activity, remain fundamental in the management of pediatric obesity, pharmacotherapy has emerged as an important adjunctive tool. This article delves into the role of pharmacotherapy in the comprehensive management of pediatric obesity, emphasizing its benefits, considerations, and potential impact on young patients' lives .
Pediatric obesity has reached alarming levels worldwide, with an increasing number of children and adolescents affected by excess body weight. It is associated with a heightened risk of numerous health problems, including type 2 diabetes, cardiovascular diseases, sleep apnea, and psychosocial issues. Effective interventions are essential to mitigate these risks and improve the overall health of young patients. Pharmacotherapy for pediatric obesity is not a stand-alone solution but rather a complementary component within a comprehensive treatment plan. It is typically considered when children and adolescents have severe obesity (defined as a body mass index, or BMI, greater than or equal to 120% of the 95th percentile) or when obesity-related comorbidities are present. The decision to incorporate pharmacotherapy should be made after thorough assessment and in consultation with healthcare providers experienced in pediatric obesity management. Patient selection: The selection of appropriate candidates for pharmacotherapy is crucial. Clinicians carefully evaluate factors such as age, BMI, comorbidities, and the readiness of the child and their family to engage in comprehensive care. FDA-Approved Medications: In the United States, two medications are FDA-approved for pediatric obesity: orlistat (Xenical, Alli) for adolescents aged 12 and older, and liraglutide (Saxenda) for adolescents aged 12 to 17. These medications work through distinct mechanisms to assist with weight management. Mechanism of action: Understanding how medications work is essential for both healthcare providers and families. For example, orlistat reduces fat absorption, which may lead to gastrointestinal side effects, while liraglutide affects appetite regulation .
Treatment plans must be individualized to suit the unique needs and preferences of each child. This includes considering potential side effects and addressing any concerns or challenges that may arise during treatment. Pharmacotherapy can assist children and adolescents in achieving modest but clinically significant reductions in body weight when combined with lifestyle modifications.Weight loss often results in improvements in obesity-related comorbidities such as insulin resistance, hypertension, and sleep apnea. Psychosocial Well-being: Successful weight management can enhance self-esteem and psychosocial well-being, potentially reducing the risk of depression and anxiety. In some cases, the incorporation of pharmacotherapy can serve as a motivating factor, encouraging children and their families to maintain healthier lifestyles .
Promising antiparasitic drug candidates
KAF156: A novel antimalarial compound, KAF156, has shown potential against both drug-sensitive and drug-resistant strains of the malaria parasite. It works by inhibiting a key protein involved in parasite proliferation. Fexinidazole: Approved for the treatment of sleeping sickness (African trypanosomiasis), fexinidazole is an example of repurposing an existing drug (originally developed for a bacterial infection) for a parasitic disease. Ozoralizumab: This experimental drug targets the liver stage of malaria parasites and has demonstrated strong potential in preclinical studies. SCYX-7158: Designed to treat Chagas disease, SCYX-7158 is a promising compound that has shown efficacy in clinical trials .
Long-term safety and efficacy data for pediatric obesity pharmacotherapy are limited. Continued research is essential to gain a deeper understanding of the effects of these medications over extended periods. Side effects: Medications may have side effects, which require careful monitoring and management. Common side effects include gastrointestinal symptoms, changes in appetite, and potential effects on growth. Multidisciplinary approach: Effective management of pediatric obesity demands a multidisciplinary approach involving healthcare providers, registered dietitians, psychologists, and robust family support. Pharmacotherapy has an important role in the comprehensive management of pediatric obesity, particularly when lifestyle interventions alone do not suffice. However, its use should be judicious and closely monitored, with a focus on the overall health and well-being of young patients. Ongoing research and the development of new medications offer hope for improved strategies to address this complex health issue. Ultimately, the goal is not just weight loss but the long-term health and quality of life of children and adolescents affected by obesity .
- Güngör NK. Overweight and obesity in children and adolescents. J Clin Res Pediatr Endocrinol. 2014;6(3):129.
- Golan M, Crow S. Targeting parents exclusively in the treatment of childhood obesity: long?term results. Obesity research. 2004;12(2):357-61.
- Whitlock EP, Williams SB, Gold R, et al. Screening and interventions for childhood overweight: a summary of evidence for the US Preventive Services Task Force. Pediatrics. 2005;116(1):e125-44.
- Herouvi D, Paltoglou G, Soldatou A, et al. Lifestyle and Pharmacological Interventions and Treatment Indications for the Management of Obesity in Children and Adolescents. Children. 2023;10(7):1230.
- Nammi S, Koka S, Chinnala KM, et al. Obesity: An overview on its current perspectives and treatment options. Nutr J. 2004;3(1):1-8.